Bayer's Fortnight of Reckoning: Board, Court, and Cash Flow in Focus

Bayer faces pivotal Supreme Court hearing on glyphosate lawsuits and AGM vote, as strong pharma sales contrast with litigation costs and negative cash flow projections.

The next two weeks are set to define Bayer’s immediate future, with a pivotal Supreme Court hearing and the company’s Annual General Meeting poised to shape the investment case. The stock, trading around €41, has nearly doubled from its April 2025 low of €20.80, yet remains roughly 17% below its February peak of €49.17.

Central to the near-term volatility is a legal showdown in Washington D.C. On April 27, the U.S. Supreme Court will hear arguments in the Durnell case, where Bayer contends that federal regulatory approvals from the EPA should preempt state-level warning requirements for glyphosate. A favorable ruling could render a significant portion of the thousands of pending lawsuits moot. This hearing occurs just as the company enters a quiet period ahead of its Q1 results on May 12, making legal developments the primary driver for the share price.

Simultaneously, Bayer is pushing forward with a $7.25 billion settlement proposal to resolve existing and future claims linking glyphosate to non-Hodgkin lymphoma. Claimants have until June 4 to opt out of this arrangement.

The corporate governance side sees changes at the top. At the virtual AGM on April 24, shareholders will vote on new supervisory board members. Alfred Stern, CEO of OMV, and former Cargill and Sara Lee executive Marcel Smits are slated to replace departing members Paul Achleitner and Colleen A. Goggins. The meeting will also see a proposed dividend of €0.11 per share, unchanged from the prior year, with an ex-dividend date of April 27 and payment on April 29.

Operationally, the pharmaceuticals division provides a bright spot. The prostate cancer drug Nubeqa saw sales surge 57% in 2025 to €2.4 billion, while the kidney disease treatment Kerendia grew 79% to €829 million. Pharma chief Stefan Oelrich has labeled 2026 as the "last flat year," anticipating mid-single-digit percentage growth from 2027 into the next decade. The company's full-year guidance remains steady, targeting sales of €45-47 billion and EBITDA before special items of €9.6-10.1 billion. Management has stated that potential U.S. import tariffs on pharmaceuticals are considered manageable and already factored into 2026 planning.

Financially, challenges persist. Management continues to project a negative free cash flow for 2026, estimated between -€1.5 and -€2.5 billion, due to roughly €5 billion in litigation-related payments. Net financial debt, which fell 8.5% to approximately €29.8 billion at the end of 2025, is targeted to be between €32 and €33 billion. There is a sliver of positive regulatory news, as Kentucky recently became the third U.S. state, after North Dakota and Georgia, to enact laws shielding Bayer from certain glyphosate lawsuits.

Analyst opinions reflect the bifurcated outlook. UBS reaffirmed a Buy rating with a €52 price target, suggesting about 27% upside from recent levels, citing strength in the pharma pipeline. DZ Bank is more cautious, upgrading its rating from Sell to Hold with a €44 fair value estimate.

The coming fortnight encapsulates Bayer’s story: a company demonstrating robust operational progress in pharmaceuticals while its financial and legal frameworks face intense, simultaneous pressure. The outcomes will likely determine whether the stock’s impressive recovery can be sustained.